HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Login (HMA-DMS)
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Veterinary Medicines
  • >CMDv
  • >Procedural guidance
  • >Post Marketing Procedures
  • >Variations
  • CMDv
    • About CMDv
    • COVID-19
    • BREXIT
    • Procedural Contact Points
    • Procedural guidance
      • General Information on Applications
      • Validation of Applications
      • Applications for Marketing Authorisation
      • Post Marketing Procedures
        • Variations
        • Renewals
        • Pharmacovigilance
      • Referrals
      • ASMF
      • SPC, Labelling and Package leaflet
      • Miscellaneous
    • Questions & Answers
    • Publications
  • VMRI Product Index
  • National Contacts

 

Variations

Best Practice Guides - Commission Regulation (EC) No. 1234/2008

Best practice guide for Type IA variations [Track version] (December 2020)

Best practice guide for Type IB variations [Track version] (December 2020)

Best practice guide for Type II variations [Track version] (December 2020)

Best practice guide for grouping of variations

Best practice guide for worksharing

Worksharing procedural update

Worksharing - applicant's letter of intent

Template for Active Substance Master File (ASMF) Type IB variation assessment report

 

Recommendations for classification of unforeseen variations
according to Article 5 of Commission Regulation (EC) 1234/2008

Veterinary applications

Human applications

Best practice guide for the classification of unforeseen variations - Article 5

Article 5 recommendation - Request form

 

Questions and answers

CMDh-CMDv Q&A List for the submission of variations according to Commission Regulation (EC) 1234/2008

CMDh-CMDv Examples of acceptible and non-acceptible groupings for MRP-DCP

European Commission procedural and classification guidance on variations

The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. HMA and CMDh/v are in the process of making appropriate changes to this website. If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. In case you notice information that should be updated, please report this website link using the contact form.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/578.html?&L=0